The study ties first-trimester Oropouche infection to severe fetal neurodevelopmental anomalies and urges RT-PCR within 2-7 ...

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using ...

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ...

Intensity Therapeutics Inc. INTS on Thursday provided an update on the INVINCIBLE-4 Study. The INVINCIBLE-4 study is a Phase ...

Pathological complete response at surgery was higher with INT230-6 pre-treatment plus Keynote-522 (5/7; 71.4%) than with Keynote-522 alone (2/6; 33%), with one evaluation pending. Grade ≥3 adverse ...

Like many who sit next to Mr Trump as he bloviates, there is a risk of the Taoiseach seeming like a bystander, watching on as Mr Trump bounces from issue to issue ...

All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing ...

Doctors address the pros and cons of Health Resources and Services Administration’s new guidance, including at-home ...

CAST, a leading provider of semiconductor intellectual property cores, today announced the TSN-EP-10G Time-Sensitive Networking (TSN) Endpoint IP core, extending its established TSN portfolio to ...

When equine herpesvirus-1 (EHV-1) swept through a Texas barrel racing event in November 2025, the consequences extended well beyond the horses involved. As events were canceled across disciplines and ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 3:00 PM EDTCompany ParticipantsEmily Leproust ...

DENVER — Studies published in a medical journal and presented at a conference showed that tecovirimat did not increase clinical resolution of mpox and may contribute to antiviral resistance for people ...